Evidence map›Paper›PMID 41163637›Full record

ReviewCureus2025

Acute Fatty Liver in Pregnancy: Literature Review.

Su Zarni, Amrita Viegas

Abstract readReview
In one paragraph

Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Su ZarniObstetrics and Gynaecology, Luton and Dunstable Hospital, Luton, GBR.
Amrita ViegasObstetrics, Luton and Dunstable Hospital, Luton, GBR.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute fatty liver of pregnancy (AFLP) is a rare but potentially life-threatening obstetric emergency that typically arises in the third trimester. Although uncommon, its rapid onset, multisystem involvement, and historically high mortality make it an essential condition for clinicians to recognize and manage promptly. Its pathogenesis has been linked to defects in fatty acid metabolism and an abnormality in mitochondrial beta oxidation is a recognised cause of AFLP in a subset of cases. The clinical significance of AFLP lies in its dramatic course and overlap with other hepatic disorders of pregnancy such as haemolysis, elevated liver enzymes and low platelets (HELLP) syndrome, preeclampsia, and viral hepatitis. Misdiagnosis or delayed recognition can result in rapid maternal and fetal deterioration. Early suspicion, timely diagnosis, and expedited delivery have transformed outcomes over the past few decades in reducing maternal and perinatal mortality. AFLP is associated with multi-organ dysfunction. Hepatic complications include jaundice, coagulopathy, hypoglycaemia, and fulminant liver failure. Systemic complications frequently reported are acute kidney injury, disseminated intravascular coagulation, pancreatitis, sepsis, and encephalopathy. Obstetric complications include postpartum haemorrhage and preterm delivery, while fetal complications range from intrauterine growth restriction and hypoglycaemia to intrauterine death. Intensive care admission is often required, and in rare cases liver transplantation may be necessary when hepatic failure does not reverse after delivery. Despite its severity, prognosis has improved dramatically with heightened clinical awareness and advances in perinatal and critical care. Maternal survival rates now improve especially in tertiary centres with timely diagnosis and intervention. Fetal prognosis is closely tied to early delivery, usually by induction or caesarean section depending on maternal and fetal stability. Fetal prognosis remains more guarded, with outcomes influenced by gestational age at diagnosis, intrauterine compromise, and neonatal complications of prematurity. AFLP represents a rare but critical complication of pregnancy, demanding rapid recognition and multidisciplinary management. Its importance is underscored not only by its acute threat to maternal and fetal survival but also by its link to underlying metabolic disorders with intergenerational implications. Literature over the recent few years demonstrates significant progress in survival outcomes, yet ongoing challenges include improving diagnostic accuracy, clarifying genetic risk, and standardizing management strategies across diverse healthcare settings. Continued research into early biomarkers, targeted therapies, and global epidemiological patterns will be vital for further improving prognosis and reducing preventable maternal and perinatal morbidity and mortality.

Indexed as

aflpicu careliver failureliver transplantationmaternal mortalitypregnancy

Identifiers

PMID41163637
PMCPMC12564985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.